Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
In this article, the clinical actions of the principal dopamine receptor stimulating agents (apomorphine and its derivatives; piribedil, rye-ergot derivatives) are discussed on the basis of their biochemical and pharmacological properties.
D001058:Apomorphine / Q000031:analogs & derivatives / Q000627:therapeutic use; D001971:Bromocriptine / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010891:Piribedil / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000502:physiology*
D011954:Receptors, Dopamine; D001971:Bromocriptine; D007980:Levodopa; D010891:Piribedil; D001058:Apomorphine